Upon treatment with DIVA2 as therapeutic cancer vaccine, transitional immune control of tumor growth was achieved by the induction of OVA257-264 -specific highly functional CD8+ T cells, characterized by IFN-γ production and cytotoxic gene signature. The gene discussed is CD8A; the disease is neoplasm.